Morphosys: Das sind die Ziele von CEO Kress & Co - DER AKTIONÄR
The Top 25 Healthcare Technology Leaders of Massachusetts for 2023 | The Healthcare Technology Report.
New CEO at Morphosys - European Biotechnology
Jean-Paul Kress, Morphosys AG: Profile and Biography - Bloomberg Markets
Abarca Announces Innovative Value-Based Contract with Biogen
Jean-Paul Kress email address & phone number | Morphosys Chairman of the Board of Management, Chief Executive Officer contact information - RocketReach
David Khougazian appointed president of Sanofi Pasteur MSD - PMLiVE
Abarca Health, Biogen ally on multiple sclerosis coverage – News is My Business
Sanofi Genzyme exec jumps ship to join Biogen
MS Therapies are Focus of Abarca-Biogen Value-based Reimbursement Contract
Jean-Paul Kress email address & phone number | Morphosys Chairman of the Board of Management, Chief Executive Officer contact information - RocketReach
Jean-Paul Kress Net Worth (2023) | wallmine
Dr. Jean-Paul Kress is new CEO of MorphoSys AG - Innovations- und Gründerzentrum Biotechnologie IZB
Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer | Morphosys de
Exhibit 99.1
Kress becomes new CEO of MorphoSys - BioM
Jean-Paul Kress - CEO at MorphoSys | The Org
Two by 2025: MorphoSys Consolidates Research, Retains Commercialization Goal
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
Jean-Paul Kress M.D. — Executive VP, President of International, Head of Global Therapeutic Operations at Biogen | Comparably
Samsung, Biogen version of AbbVie's Humira approved in Europe | Reuters
What Biogen CFO's Departure Means for Company's M&A Strategy | BioSpace
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
NYC Startup Syntimmune Names Former Biogen Exec as New CEO | BioSpace
